191 related articles for article (PubMed ID: 27133481)
1. Synthesis and optimization of N-heterocyclic pyridinones as catechol-O-methyltransferase (COMT) inhibitors.
Zhao Z; Harrison ST; Schubert JW; Sanders JM; Polsky-Fisher S; Zhang NR; McLoughlin D; Gibson CR; Robinson RG; Sachs NA; Kandebo M; Yao L; Smith SM; Hutson PH; Wolkenberg SE; Barrow JC
Bioorg Med Chem Lett; 2016 Jun; 26(12):2952-2956. PubMed ID: 27133481
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of nitrocatechol chalcone and pyrazoline derivatives as inhibitors of catechol-O-methyltransferase and monoamine oxidase.
Hitge R; Smit S; Petzer A; Petzer JP
Bioorg Med Chem Lett; 2020 Jun; 30(12):127188. PubMed ID: 32299731
[TBL] [Abstract][Full Text] [Related]
3. Design of Potent and Druglike Nonphenolic Inhibitors for Catechol O-Methyltransferase Derived from a Fragment Screening Approach Targeting the S-Adenosyl-l-methionine Pocket.
Lerner C; Jakob-Roetne R; Buettelmann B; Ehler A; Rudolph M; Rodríguez Sarmiento RM
J Med Chem; 2016 Nov; 59(22):10163-10175. PubMed ID: 27685665
[TBL] [Abstract][Full Text] [Related]
4. Novel, non-nitrocatechol catechol-O-methyltransferase inhibitors modulate dopamine neurotransmission in the frontal cortex and improve cognitive flexibility.
Byers S; Buchler IP; DePasquale M; Rowley HL; Kulkarni RS; Pinder L; Kolobova A; Li C; Au V; Akuma D; Zhang G; Wei H; Cheetham SC; Barrow JC; Carr GV
Psychopharmacology (Berl); 2020 Sep; 237(9):2695-2707. PubMed ID: 32474681
[TBL] [Abstract][Full Text] [Related]
5. Identification of Potential Off-target Toxicity Liabilities of Catechol-O-methyltransferase Inhibitors by Differential Competition Capture Compound Mass Spectrometry.
von Kleist L; Michaelis S; Bartho K; Graebner O; Schlief M; Dreger M; Schrey AK; Sefkow M; Kroll F; Koester H; Luo Y
J Med Chem; 2016 May; 59(10):4664-75. PubMed ID: 27074629
[TBL] [Abstract][Full Text] [Related]
6. Optimization of 8-Hydroxyquinolines as Inhibitors of Catechol O-Methyltransferase.
Buchler I; Akuma D; Au V; Carr G; de León P; DePasquale M; Ernst G; Huang Y; Kimos M; Kolobova A; Poslusney M; Wei H; Swinnen D; Montel F; Moureau F; Jigorel E; Schulze MED; Wood M; Barrow JC
J Med Chem; 2018 Nov; 61(21):9647-9665. PubMed ID: 30272964
[TBL] [Abstract][Full Text] [Related]
7. Crystal Structure of Catechol O-Methyltransferase Complexed with Nitecapone.
Iijima H; Takebe K; Suzuki M; Kobayashi H; Takamiya T; Saito H; Niwa N; Kuwada-Kusunose T
Chem Pharm Bull (Tokyo); 2020; 68(5):447-451. PubMed ID: 32378542
[TBL] [Abstract][Full Text] [Related]
8. The inhibition of catechol O-methyltransferase and monoamine oxidase by tetralone and indanone derivatives substituted with the nitrocatechol moiety.
de Beer AD; Legoabe LJ; Petzer A; Petzer JP
Bioorg Chem; 2021 Sep; 114():105130. PubMed ID: 34225162
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of human catechol-O-methyltransferase-mediated dopamine O-methylation by daphnetin and its Phase II metabolites.
Liang SC; Ge GB; Xia YL; Pei-Pei D; Ping W; Qi XY; Cai-Xia T; Ling Y
Xenobiotica; 2017 Jun; 47(6):498-504. PubMed ID: 27435571
[TBL] [Abstract][Full Text] [Related]
10. Distribution, properties, and inhibitor sensitivity of zebrafish catechol-O-methyl transferases (COMT).
Semenova S; Rozov S; Panula P
Biochem Pharmacol; 2017 Dec; 145():147-157. PubMed ID: 28844929
[TBL] [Abstract][Full Text] [Related]
11. Peripheral and central inhibitors of catechol-O-methyl transferase: effects on liver and brain COMT activity and L-DOPA metabolism.
Brannan T; Prikhojan A; Yahr MD
J Neural Transm (Vienna); 1997; 104(1):77-87. PubMed ID: 9085195
[TBL] [Abstract][Full Text] [Related]
12. Development of Blood-Brain Barrier Permeable Nitrocatechol-Based Catechol O-Methyltransferase Inhibitors with Reduced Potential for Hepatotoxicity.
Silva T; Mohamed T; Shakeri A; Rao PP; Martínez-González L; Pérez DI; Martínez A; Valente MJ; Garrido J; Uriarte E; Serrão P; Soares-da-Silva P; Remião F; Borges F
J Med Chem; 2016 Aug; 59(16):7584-97. PubMed ID: 27463695
[TBL] [Abstract][Full Text] [Related]
13. Nordihydroguaiaretic Acid as a Novel Substrate and Inhibitor of Catechol
Kim JH; Lee J; Jeong H; Bang MS; Jeong JH; Chang M
Molecules; 2021 Apr; 26(7):. PubMed ID: 33916785
[TBL] [Abstract][Full Text] [Related]
14. Membrane bound catechol-O-methytransferase is the dominant isoform for dopamine metabolism in PC12 cells and rat brain.
Su Y; DePasquale M; Liao G; Buchler I; Zhang G; Byers S; Carr GV; Barrow J; Wei H
Eur J Pharmacol; 2021 Apr; 896():173909. PubMed ID: 33503461
[TBL] [Abstract][Full Text] [Related]
15. Inhibitory Effect of Bovine Lactoferrin on Catechol-O-Methyltransferase.
Ikeda M; Iijima H; Shinoda I; Iwamoto H; Takeda Y
Molecules; 2017 Aug; 22(8):. PubMed ID: 28825621
[TBL] [Abstract][Full Text] [Related]
16. Insight into the Therapeutic Potential of a Bicyclic Hydroxypyridone Compound 2-[(2,4-Dichlorophenyl)methyl]-7-hydroxy-1,2,3,4-tetrahydro-8H-pyrido[1,2-a]pyrazin-8-one as COMT Inhibitor in the Treatment of Parkinson's Disease: A Molecular Dynamic Simulation Approach.
Subair TI; Akawa OB; Soremekun OS; Olotu FA; Soliman MES
Chem Biodivers; 2021 Sep; 18(9):e2100204. PubMed ID: 34252268
[TBL] [Abstract][Full Text] [Related]
17. Identification and optimization of nitrophenolic analogues as dopamine metabolic enzyme inhibitors for the treatment of Parkinson's disease.
Zou M; Wu Y; Lan Y; Xie H; Sun H; Liu W; Feng F; Jiang X
Bioorg Chem; 2024 Jul; 148():107488. PubMed ID: 38797066
[TBL] [Abstract][Full Text] [Related]
18. CGP 28014, a new inhibitor of cerebral catechol-O-methylation with a non-catechol structure.
Waldmeier PC; Baumann PA; Feldtrauer JJ; Hauser K; Bittiger H; Bischoff S; von Sprecher G
Naunyn Schmiedebergs Arch Pharmacol; 1990 Sep; 342(3):305-11. PubMed ID: 1980718
[TBL] [Abstract][Full Text] [Related]
19. Design, synthesis and evaluation of 3-hydroxypyridin-4-ones as inhibitors of catechol-O-methyltransferase.
de Beer J; Petzer JP; Lourens ACU; Petzer A
Mol Divers; 2021 May; 25(2):753-762. PubMed ID: 32108308
[TBL] [Abstract][Full Text] [Related]
20. Effect of the new selective COMT inhibitor CGP 28014 A on the formation of 3-O-methyldopa (3OMD) in plasma of healthy subjects.
Bieck PR; Nilsson E; Antonin KH
J Neural Transm Suppl; 1990; 32():387-91. PubMed ID: 2128511
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
